Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer

OBJECTIVE: To explore the genetic changes in the progression of castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC) and the reason why these cancers resist existing therapies. METHODS: We employed our CRPC cell line microarray and other CRPC or NEPC datasets to scre...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qiong, Li, Zean, Yang, Jin, Peng, Shirong, Zhou, Qianghua, Yao, Kai, Cai, Wenli, Xie, Zhongqiu, Qin, Fujun, Li, Hui, Chen, Xu, Li, Kaiwen, Huang, Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425180/
https://www.ncbi.nlm.nih.gov/pubmed/34591415
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425180/
https://www.ncbi.nlm.nih.gov/pubmed/34591415
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0550

Ejemplares similares